Search

Your search keyword '"Oehme, Ina"' showing total 309 results

Search Constraints

Start Over You searched for: Author "Oehme, Ina" Remove constraint Author: "Oehme, Ina"
309 results on '"Oehme, Ina"'

Search Results

2. Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines

8. Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM

10. PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum

11. Glutaredoxin 3 (GLRX3) confers a fusion oncogene-dependent vulnerability to Ewing sarcoma

12. Somatic gene delivery for flexible in vivo modeling of high-risk sarcoma

15. Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells

17. Table S4 from The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma

18. Supplemental Table Legend from The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma

19. Figure S1, Figure S2, Figure S3, Figure S4 from The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma

20. Supplementary Data from HDAC5 and HDAC9 in Medulloblastoma: Novel Markers for Risk Stratification and Role in Tumor Cell Growth

22. Selective degradation of mutant FMS-like tyrosine kinase-3 requires BIM-dependent depletion of heat shock proteins

23. Key Pharmacokinetic Parameters of 74 Pediatric Anticancer Drugs Providing Assistance in Preclinical Studies.

24. Chromosome 8 gain drives poor patient outcome via expression of 4E-BP1 in Ewing sarcoma

27. Aza-SAHA Derivatives Are Selective Histone Deacetylase 10 Chemical Probes That Inhibit Polyamine Deacetylation and Phenocopy HDAC10 Knockout

29. BH3 mimetics targeting BCL-XL impact the senescent compartment of pilocytic astrocytoma

31. The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models

32. Design, Synthesis and Biological Characterization of Histone Deacetylase 8 (HDAC8) Proteolysis Targeting Chimeras (PROTACs) with Anti-Neuroblastoma Activity

33. Abstract 5221: The first-in-class ERK inhibitor ulixertinib (BVD-523) shows activity in MAPK-driven pediatric low-grade glioma models as single agent and in combination with MEK inhibitors or senolytics

34. First Fluorescent Acetylspermidine Deacetylation Assay for HDAC10 Identifies Selective Inhibitors with Cellular Target Engagement**

36. LGG-25. The first-in-class ERK inhibitor ulixertinib (BVD-523) shows activity in MAPK-driven pediatric low-grade glioma models as single agent and in combination with MEK inhibitors or senolytics

37. LGG-18. Inhibition of Bcl-xL targets the senescent compartment of pilocytic astrocytoma

38. MODL-04. Drug screening in Disorders with Abnormal DNA Damage Response/Repair (DADDR) andin vivo validation

39. DDEL-01. The role of key pharmacodynamic and pharmacokinetic parameters in drug response prediction of pediatric tumors in the precision oncology study INFORM

43. Histone deacetylase 10 promotes autophagy-mediated cell survival

44. Identification of HDAC10 Inhibitors that Modulate Autophagy in Transformed Cells

45. Functional Therapeutic Target Validation Using Pediatric Zebrafish Xenograft Models

46. Autophagy

47. Identification of HDAC10 Inhibitors that Modulate Autophagy-Related Proteins in Transformed Cells

48. Predictive modeling of resistance to SMO inhibition in a patient-derived orthotopic xenograft model of SHH medulloblastoma

49. iTReX: Interactive exploration of mono- and combination therapy dose response profiling data

50. ERBB and P‐glycoprotein inhibitors break resistance in relapsed neuroblastoma models through P‐glycoprotein.

Catalog

Books, media, physical & digital resources